Pharmacology of HIV Treatment and Antivirals against Hepatitis Viruses

Dear Colleagues,

Therapies for HIV infection as well as hepatitis C have significantly evolved in recent years. Newer antiretrovirals have overcome significant obstacles such as side effects, high daily pill burden, lack of efficacy, resistances, or limited access to therapy, and now, most patients receive simple therapies, mostly consisting of single-tablet regimens or long-acting injectable drugs, achieving long-lasting virological response. Furthermore, HIV might also benefit from monoclonal antibodies, which may dramatically change HIV therapy as we currently know it. Direct-acting antivirals for hepatitis C infection have radically changed the lives of millions of patients worldwide, achieving a remarkable efficacy with short, simple treatment regimens. This therapeutic revolution has turned a complex chronic infection with limited treatment options into an eradicable disease, as seen in several population-scale trials. The development of new antivirals against hepatitis B and D brings hope for so many patients who are still waiting for novel strategies that may provide a cure for this infection.

The aim of this Special Issue is to provide updated information on new antiretrovirals and antivirals against hepatitis viruses, as well as newer treatment strategies and drug delivery methods.

Dr. José Vicente Fernández-Montero
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• long-acting injectable antiretrovirals
• broadly neutralizing antibodies
• direct-acting antivirals
• entry inhibitors
• drug administration
• HIV-2
• HTLV
• antiviral drugs
• HIV and viral hepatitis vaccines